Israel - English - Ministry of Health

j-c health care ltd - haloperidol - tablets - haloperidol 5 mg - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Israel - English - Ministry of Health

j-c health care ltd - haloperidol - solution (oral) - haloperidol 2 mg/ml - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - ibuprofen, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections; arginine - caldolor injection is indicated in adults for the management of acute mild to moderate post-operative pain and moderate to severe post-operative pain with adjunctive reduced morphine dosage, where an intravenous route of administration is considered clinically necessary.,caldolor is indicated for the reduction of fever in adults where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - ibuprofen, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: arginine; water for injections; hydrochloric acid - caldolor injection is indicated in adults for the management of acute mild to moderate post-operative pain and moderate to severe post-operative pain with adjunctive reduced morphine dosage, where an intravenous route of administration is considered clinically necessary.,caldolor is indicated for the reduction of fever in adults where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - haloperidol decanoate, quantity: 70.52 mg/ml (equivalent: haloperidol, qty 50 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; sesame oil - haldol decanoate is indicated for the maintenance therapy of psychoses in adults; particularly for patients requiring prolonged parenteral neuroleptic therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - haloperidol - solution for injection - 100 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - haloperidol - solution for injection - 50 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - haloperidol - solution for injection - 100 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - haloperidol - solution for injection - 50 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharma limited - haloperidol - solution for injection - butyrophenone derivatives; haloperidol